Amphastar Pharmaceuticals, Inc. $AMPH Shares Purchased by Hotchkis & Wiley Capital Management LLC

Key Points

• Hotchkis & Wiley Capital Management LLC increased its stake in Amphastar Pharmaceuticals by 13.7%, purchasing an additional 32,630 shares to hold a total of 270,150 shares valued at $7.8 million.
• Amphastar Pharmaceuticals' stock has a market capitalization of $1.42 billion, with a current PE ratio of 11.42 and trading near $30.50.
• Analysts have mixed ratings on Amphastar, with a current average price target of $31.50, reflecting two "Buy" ratings and two "Hold" ratings among research analysts.

Hotchkis & Wiley Capital Management LLC boosted its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 13.7% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 270,150 shares of the company's stock after purchasing an additional 32,630 shares during the period. Hotchkis & Wiley Capital Management LLC owned about 0.57% of Amphastar Pharmaceuticals worth $7,832,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in AMPH. Signaturefd LLC raised its position in shares of Amphastar Pharmaceuticals by 147.7% in the first quarter. Signaturefd LLC now owns 872 shares of the company's stock worth $25,000 after acquiring an additional 520 shares during the period. GF Fund Management CO. LTD. acquired a new position in shares of Amphastar Pharmaceuticals in the fourth quarter worth about $38,000. Tower Research Capital LLC TRC raised its position in shares of Amphastar Pharmaceuticals by 43.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock worth $43,000 after acquiring an additional 348 shares during the period. IFP Advisors Inc acquired a new position in shares of Amphastar Pharmaceuticals in the first quarter worth about $34,000. Finally, GAMMA Investing LLC raised its position in shares of Amphastar Pharmaceuticals by 46.6% in the first quarter. GAMMA Investing LLC now owns 1,333 shares of the company's stock worth $39,000 after acquiring an additional 424 shares during the period. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Price Performance

AMPH traded up $0.36 on Friday, reaching $30.62. 290,925 shares of the company's stock were exchanged, compared to its average volume of 638,844. The stock has a market cap of $1.42 billion, a PE ratio of 11.47 and a beta of 0.76. Amphastar Pharmaceuticals, Inc. has a twelve month low of $20.39 and a twelve month high of $53.96. The stock's fifty day moving average price is $24.60 and its 200-day moving average price is $25.75. The company has a debt-to-equity ratio of 0.80, a current ratio of 3.29 and a quick ratio of 2.21.

Analyst Ratings Changes

A number of brokerages have weighed in on AMPH. JPMorgan Chase & Co. reiterated a "neutral" rating and issued a $30.00 price objective (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 12th. Needham & Company LLC upgraded shares of Amphastar Pharmaceuticals from a "hold" rating to a "buy" rating and set a $36.00 price objective for the company in a research report on Tuesday, August 12th. Piper Sandler decreased their price objective on shares of Amphastar Pharmaceuticals from $30.00 to $25.00 and set a "neutral" rating for the company in a research report on Friday, August 8th. Wells Fargo & Company decreased their price objective on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a research report on Thursday, May 8th. Finally, Bank of America upped their price objective on shares of Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the stock a "neutral" rating in a research report on Tuesday. Two analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, Amphastar Pharmaceuticals has a consensus rating of "Hold" and an average price target of $31.60.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.